-
Information courtesy of Goran Ilic
Translation for BabelFAmily: Sarah Uhl
December 19, 2011. The Commission for the Italian Higher Institute for Health, the authority responsible for launching the phase one clinical trial of RG2833, and the Ethical Comm...
-
Translation for BabelFAmily by: Caroline Williamson
Three books in three years. The challenge has been met and Maria is pleased. Next Monday, 21st November, she launches the third, ‘El Castillo de Albanza’ (‘The Castle of Albanza’), at a festiv...
-
Abstract kindly supplied by Juan Carlos Baiges through FAPG
Received 22 September 2011; revised 17 October 2011; Accepted 17 October 2011. Available online 21 October 2011.
Science Direct abstract link...
-
News kindly supplied by Kresimir Babic
Bach Pharma, Inc. and Destum Partners, Inc. - Corporate Development Initiatives
FOR IMMEDIATE RELEASE NORTH ANDOVER, Massachusetts – October 31, 2011 – Bach Pharma, Inc. (Bach), a privately held drug devel...
-
ScienceDaily (Nov. 3, 2011) - When Dr. John Fryer and Dr. Huda Zoghbi prescribed mild exercise for mice with a neurodegenerative disorder called spinocerebellar ataxia 1 (SCA1), they did not know what to expect.Fryer, then a postdoctoral associate in the ...
-
Dr. Pierre Rustin’s power point presentation at the 2011 euro-Ataxia meeting
See/click here...
-
October 31, 2011
(…) During the quarter, ViroPharma in-licensed worldwide rights to OX1 from Intellect Neurosciences. OX1 is being developed for the treatment of Friedreich’s ataxia (FA), a rare, hereditary, progressive neurodegenerative disease. Vir...
-
ScienceDaily (Oct. 17, 2011) - A protein that promotes the growth of neurons and blood vessels appears to stop the progression of a genetic disease that causes degeneration of the cerebellum, according to new preclinical Northwestern Medicine research pub...
-
Ataxia UK and the Friedreich’s Ataxia Society Ireland are pleased to announce that they will be hosting an international research conference in London from 1 to 3 November 2012.
The conference will include sessions on a wide range of progressive atax...
-
In development.
This documentary portrays the creative process of writers suffering from Friedreich’s Ataxia disease that are coming together to author a special, collaborative novel that will be sold in bookstores to collect funds for scientific res...
-
September 30 2011 (RTTNews) - ViroPharma Inc. Friday announced the license of worldwide rights from Intellect Neurosciences, Inc. to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia, a rare, hereditary, prog...
-
Info kindly supplied through Internaf by Juan Carlos Baiges
See: http://clinicaltrials.gov/ct2/show/NCT01350440
...
-
Preliminary trial findings shared with FARA-USF research symposium participants
News kindly supplied by Juan Carlos Baiges
August 31, 2011
For the first time, an investigative drug has significantly improved the neurological function of patients ...
-
News kindly supplied by Goran Ilic
Spring 2011 - MDA has awarded a research grant totaling $625,959 over a period of three years to Des Richardson, professor and senior principal research fellow at the University of Sydney (Australia) School of Medical...
-
Battling Through Life is a moving, touching, funny, and sometimes painful revelation of the trials and tribulations Filomena and her family have faced in trying to deal and cope with an insidious disease, Friedreich's ataxia (a slowly progressive neurom...
-
News kindly supplied by Goran Ilic
Tampa, FL (Aug. 19, 2011) – Scientists, clinicians and patients will gather Aug. 25 at the University of South Florida to discuss research progress that may lead to therapies for Friedreich’s ataxia and related diso...
-
(...) "The European Medicines Agency (European Union’s FDA equivalent) has assented to Repligen’s proposal of a phase I clinical trial of RG2833 in FA patients. Repligen is now seeking the permission of the Italian government and the ethics committee ...
-
News kindly supplied by Kresimir Babic
10 August 2011
(….) Lu AA24493 is an interesting tissue protective cytokine with potential for addressing medical needs in a number of severe CNS diseases. In November 2009, Lundbeck initi...
-
EFACTS (the European Friedreich’s Ataxia Consortium for Translational Studies) assembles a body of expertise to adopt a translational research strategy for the rare autosomal recessive neurological disease, Friedreich’s ataxia (FRDA). FRDA is a severe...
-
Press release - for immediate release
Whitby, Ontario to host 3rd “The Walk to Fight Familial Ataxias” (FA) on September 24, 2011 from 10 a.m. to 1 p.m. Heydenshore Park, 589 Water Street. Richmond, BC to host 1st “The Walk to Fight Fam...
News archive 
